DHTKD1 and neoplasm: To test whether increasing the transactivation of sensory switch circuits can improve the OV efficacy against tumor, we developed a modified Hepa1-6 cell line (mHepa1-6) that constitutively express Gal4VP16 to activate the coexpression of E1A and immune effector after OV-Effector treatment (Supplementary Fig. 7a).